Financial Reports 2019

Quarterly Report 2019 Q1

Issue link: https://resources.liminalbiosciences.com/i/1116424

Contents of this Issue

Navigation

Page 1 of 54

1 Press Release for immediate release PROMETIC REPORTS ITS 2019 FIRST QUARTER FINANCIAL RESULTS • Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering • New CEO, Board appointees and management structure to strengthen Corporation's leadership • $8.2 million in revenues for Q1-2019 compared to $4.3 million for Q1-2018 • Net loss of $28.8 million for Q1-2019 compared to Net loss $34.6 million for Q1-2018 LAVAL, QUEBEC, CANADA – May 8, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Corporation") reported today its unaudited financial results for the first quarter ended March 31, 2019. "We are pleased to have completed the recapitalization transactions and equity offering in April that have provided both an improved capital structure and necessary cash liquidity from the $ 75 million gross proceeds received from Structured Alpha LP and Consonance Capital Management", stated Mr. Kenneth Galbraith, Chief Executive Officer. "In addition, the Corporation expects to commence the previously-announced rights offering in the coming weeks, which could provide up to a maximum of $75 million in additional gross proceeds to the Corporation". "We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) ("Ryplazim TM ") BLA before the end of 2019. In addition, our bioseparations business had an excellent quarter with revenue growth of 55% compared to the same quarter in 2018." "We look forward to reporting further progress on our business and R&D activities in the coming months and appreciate the continued support of our shareholders in helping to build a successful and focused global life sciences corporation, with the potential to address unmet medical needs of patients with serious diseases in multiple therapeutic areas of interest", added Mr. Galbraith.

Articles in this issue

Links on this page

view archives of Financial Reports 2019 - Quarterly Report 2019 Q1